Facet arthropathy is osteoarthritis of the small paired joints at the back of each spinal segment, and it matters because those joints can become a pain generator in their own right. If you are weighing regenerative options in 2026, the decision does not start with choosing an injection. It starts with confirming that the facet joints are actually the source of your pain, because an orthobiologic aimed at the wrong structure cannot help no matter how it is prepared.
Key takeaways
- Facet arthropathy is arthritis in the small joints of the spine, and symptoms typically worsen with extension and rotation rather than with bending forward.
- In a 2025 systematic review, the facet joints were identified as the pain source in 15% to 41% of patients with chronic low back pain.
- Orthobiologics are target-specific. A plan built for a disc will not address a facet joint, and the reverse is equally true.
- The randomized data comparing platelet-rich plasma with corticosteroid in facet joints is small and short-term. It is a reason to discuss PRP, not a reason to expect a fixed result.
- No orthobiologic has been shown to regrow or regenerate cartilage, and we do not describe any of them that way.
- Conservative care comes first. Surgery is considered only after conservative measures have been exhausted.
What facet arthropathy actually is
The joints involved
Every spinal segment has a pair of facet joints at the back that guide and limit motion. Like other synovial joints they have cartilage and a capsule, and they can develop arthritic change, bone spurs, and capsular inflammation. Cleveland Clinic’s patient education describes facet arthropathy as arthritis affecting these small spinal joints, with cartilage wear that allows bone surfaces to rub.
Who tends to develop it
Cleveland Clinic lists risk factors for facet arthropathy in adults that include being above age 45 and having a BMI over 25, along with disc degeneration, physically demanding work, weak spinal support muscles, and prior spinal surgery or injury. That list is one reason we look at the wider metabolic picture rather than treating a joint in isolation. Body composition and inflammatory load are part of the terrain the joint sits in.
Why the source matters more than the label
Clinicians generally describe where pain is coming from rather than sorting facet pain into distinct types. The practical consequence is simple: the target anatomy has to match the suspected source before any injection is worth discussing.
Confirming the pain generator comes first
How common facet-mediated pain is
In a 2025 systematic review of treatments for hypertrophic facet joints, the facet joints were identified as the source in 15% to 41% of patients with chronic low back pain. That is a wide range, and it carries a useful message in both directions. Facet involvement is common enough that it should be looked for, and far from universal enough that it should not be assumed.
What the evaluation covers
We work through your symptom pattern, examination findings, and imaging in context, then match options to the most likely source. Imaging alone rarely settles the question, because degenerative change on a scan is common in people without pain.
Conservative care first, then reassess
We begin with conservative measures and monitor the response before escalating. When symptoms persist, we reassess the anatomy and the goal of care rather than moving directly to the most aggressive available option.
What the evidence says about PRP in the facet joints
PRP is not one product
Platelet-rich plasma varies by preparation, platelet concentration, leukocyte content, and injected volume, and studies compare different formulations rather than a single standard treatment. When you read a PRP result, you are reading a result for that protocol in that population.
The randomized comparisons that get quoted
The 2025 systematic review summarizes a randomized trial in which 46 participants with facet-joint pain were divided into a group receiving 0.5 mL of platelet-rich plasma and a group receiving 1.5 mL of methylprednisolone, with the PRP group reported to reach an 80.96% success rate. The same review describes a second randomized comparison in 40 participants with facet-joint pain in which PRP showed 90% effectiveness against 75% for corticosteroid.
Both are small trials with their own definitions of success, and neither establishes a durable structural change in the joint. We use figures like these to set expectations and to explain where the evidence stops, not as a forecast for any individual patient.
Where BMAC, Lipogems, and intradiscal orthobiologics fit
Marrow- and fat-derived options
Bone marrow aspirate concentrate and Lipogems are discussed when the clinical goal and the anatomy line up, with an explicit account of what is known and what is not. They are considered inside a conservative-first plan, not as a shortcut past one. You can read what each option involves on our orthobiologics service page.
When the disc, not the facet, is the driver
Some presentations point to a disc contributor rather than a facet one, and intradiscal orthobiologics enter the discussion only when the evaluation supports that. The point of a source-specific plan is to avoid treating the wrong structure well.
Knee language does not transfer to the spine
Patients often arrive using knee terms such as bone-on-bone. In advanced knee osteoarthritis, trial authors frame platelet-rich plasma as a safe bridge therapy prior to joint replacement, not as something that rebuilds cartilage. Facet joints are a different anatomy with a different evidence base, so we keep the two conversations separate.
Peptide and longevity medicine: a separate conversation
What these topics are and are not
Peptide and longevity medicine come up when patients want a broader, longer-horizon view of their health. At Regen.MD these are discussed as clinical and educational subjects. They are not sold, and they are not a substitute for identifying the structure generating your back pain.
Where the metabolic picture does connect
Inflammation, tissue environment, and metabolic patterns influence how tissue tolerates load and how quickly it recovers. That is a legitimate part of a long-term plan, and it belongs alongside the procedural decision rather than inside it.
Who you see
Dr. Gurpreet Singh Padda, MD, MBA, MHP
Dr. Gurpreet Singh Padda, MD, MBA, MHP directs Regen.MD and leads the Clinical Evaluation. He is a surgeon, and the practice does provide surgery when conservative measures have been exhausted. That is precisely why the conservative pathway is taken seriously first rather than treated as a formality.
How decisions get made
The goal of the evaluation is comprehensive information, so you can understand your condition, weigh the limits of the evidence, and be involved in the decision. The office is at 4477 Woodson Rd, Suite 103, St. Louis, MO 63134, next to St. Louis Lambert International Airport; details are on our St. Louis location page.
Find out whether your facet joints are the problem
Regen.MD begins with a physician-led Clinical Evaluation — a review of your history, imaging, and metabolic data, and a written terrain roadmap. Evaluation is contingent upon review of your data.
Questions? Call (314) 295-3000 or text (314) 886-5902.
Frequently asked questions
What is facet arthropathy, and how is it different from disc pain?
Facet arthropathy is arthritis in the small paired joints at the back of each spinal segment, while disc pain comes from the cushion between the vertebral bodies. The two can coexist, and they call for different targets, which is why the evaluation has to sort them out before any injection is planned. You can review how we work through the conditions we evaluate and the pathways that follow.
Does platelet-rich plasma work for facet joint pain?
The randomized evidence is small and short-term. A 2025 systematic review summarizes two randomized comparisons in which platelet-rich plasma performed at least as well as corticosteroid in participants with facet-joint pain, but neither trial establishes a durable structural change. Our patient education library explains how we read this kind of evidence.
Will an orthobiologic injection rebuild the cartilage in my facet joints?
No. No orthobiologic has been shown to regrow or regenerate cartilage, and we do not present any injection that way. The realistic goals are symptom reduction and better tolerance of loading and rehabilitation, which is the frame we use in our approach to care.
Are peptides part of treating facet arthropathy?
Peptides are discussed here as clinical and educational subjects, not as a product and not as a treatment for a specific spinal joint. If your questions run toward metabolic and longevity topics, start with our physician-directed peptide therapy education and keep it separate from the spine decision.
Who performs the evaluation?
The Clinical Evaluation is physician-led and includes a review of your history, imaging, and metabolic data. You can read the background and training of Dr. Gurpreet Singh Padda, MD, MBA, MHP before you decide whether to request one.
Sources
- Hawkins N, García A, López-Candelas F, et al. Overview of Available Treatments and Their Limitations for Hypertrophic Facet Joints — A Systematic Review of the Literature. Journal of the American Academy of Orthopaedic Surgeons: Global Research and Reviews, 2025;9(1):e24.00140. https://pmc.ncbi.nlm.nih.gov/articles/PMC11703435/ — referenced for the 15% to 41% facet-source range in patients with chronic low back pain, the 46-participant PRP versus methylprednisolone comparison and its 80.96% success rate, and the 40-participant comparison reporting 90% effectiveness for PRP against 75% for corticosteroid.
- Cleveland Clinic. Facet Arthropathy. Patient education article, accessed August 2026. https://my.clevelandclinic.org/health/diseases/facet-arthropathy — referenced for the definition of facet arthropathy and the adult risk factors of age above 45 and BMI over 25.